Ooki A, Morita S, Iwamoto S, et al. - Researchers investigated if there is any clinical influence of patients’ self-perceptions of symptoms at baseline on prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients managed with the first-line cetuximab and standard chemotherapy, by utilizing data from a prospective trial evaluating the links between quality of life, treatment efficacy, and adverse events (AEs). This study included 137 mCRC patients. Findings revealed a link of baseline symptoms with the worse overall survival but not with impaired treatment efficacy or more frequent AEs in mCRC patients managed with cetuximab in addition to chemotherapy.